Cathepsin S is a protease that is upregulated in multiple tumour types. Using a syngeneic murine model, we were able to evaluate the contribution of cathepsin S from both tumour and tumour-associated cells, clearly showing for the first time that both sources can contribute this protease to promote tumourigenesis. These results reveal a mechanism by which tumour and recruited cells cooperate in tumour development and validate cathepsin S as an anti-angiogenic and anti-proliferative drug target.
Introduction
Cathepsin S (CatS) is a cysteine protease, found abundantly in antigen presenting cells (APCs), where it is known to have key roles in MHC class II antigen processing and presentation. 1, 2 This potent elastinolytic and collagenolytic enzyme is unique amongst the 11 human lysosomal cysteine cathepsins due to its ability to retain its activity in more neutral pH conditions, such as the extracellular environment. 3, 4 Consequently, CatS has been implicated in a number of disease states, where it is secreted and promotes the remodelling of extracellular matrix (ECM) components, especially in conditions such as rheumatoid arthritis, atherosclerosis and cancer. [5] [6] [7] [8] [9] [10] Clinically, the up-regulation of CatS in tumours has been observed in prostate, gastric, colorectal and brain tumours. [11] [12] [13] [14] Indeed, in astrocytomas, increased CatS levels correlate with advancing tumour grade and a poorer patient prognosis. 15, 16 In addition, we have recently observed similar prognostic value in colorectal cancer (CRC), detecting marked up-regulation in all tumour stages. 13, 17 Further insight into the role(s) of CatS in tumour development has been provided using murine tumour models. CatS null (CatS -/-) mice crossed with the spontaneous pancreatic beta cell carcinogenesis model (RIP1-Tag2) established that CatS can promote tumourigenesis through increased invasiveness, activation of angiogenesis and tumour neo-vascularisation. 10, 18 It highlighted that a major source of CatS in these tumours was infiltrating tumour-associated macrophages (TAMs). 19 However, our previous analyses 5 of human tumour cell lines and clinical biopsies from brain and colorectal carcinomas demonstrated that tumour cells also produce significant levels of this protease. [13] [14] [15] [16] [17] 20 Therefore, in this current investigation, we wished to further evaluate the role and the cellular contribution of CatS in a syngeneic immuno-competent CRC tumour model, comparing both C57Bl/6 wild type (WT) and CatS -/mice. These studies show a clear contribution of CatS from both tumour and tumour-associated cells, which promote angiogenesis and tumour progression, validating its potential as a therapeutic target.
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The PCR products were visualized by agarose gel electrophoresis on a 1% gel.
Retroviral transfection and transductions
Murine CatS-specific short-hairpin RNAs (shRNA) and control constructs in pGFP-V-RS (10 µg) (OriGene Technologies) were transfected with packaging vector pCL-ECO (3.3 µg) into PlatE cells (Invitrogen, UK) using Lipofectamine 2000 (Invitrogen, UK). After 72 h, 1 ml viral supernatants were collected, filtered through a 0.45 µm filter and mixed with 1 ml of fully supplemented DMEM containing 6 µg/ml PolyBrene (Sigma, UK) and added to MC38 cells (2 x 10 5 ). 24 hr post-infection, medium was replenished and stable cells selected in puromycin (10 µg/ml) for a minimum of 14 days.
Cellular Characterisation Assays
Invasion assays were performed as previously described using the CatS inhibitory antibody, Fsn0503 (Fusion Antibodies, UK). 13 
Assessment of vessel functionality
Fluorescein-labelled lectin (Lycopersicon esculentum) (Sigma, UK) was injected into the tail vein (1 mg/ml, 100 µl/mouse) and allowed to circulate for 5 min prior to heart perfusion with 10% formalin for 5 min. Tumours were excised, embedded in optimal cutting temperature (OCT) compound and 9 sectioned at 10 µm thickness before mounting with Vectashield containing DAPI (Vectorlabs, UK). Tumour vessel permeability was assessed via Evan's blue perfusion for 60 min (tail vein injection, 20 mg/ml, 100 µl/mouse), prior to formalin fixation. Evan's blue content of excised, dried tumours was determined after formamide extraction at 620 nm.
Immunohistochemistry of tumour samples and analysis
Tumour sections were formalin fixed, paraffin-embedded and subjected to immuno-staining as previously described. 13 Antibodies and concentrations used were as follows; rat anti-mouse CD34 (1:50) (Abcam), rabbit anti-human 
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For the analysis of tumour growth, tumour vessel number, tumour vessel area, proliferation rate and apoptosis, the mean and SEM was established from all tumours in each group investigated. The statistical analyses were performed using the Student t-test to obtain the p value within each parameter.
Results
CatS is expressed in murine tumour cell lines
In this current investigation, an immuno-competent tumour model was used to study the contribution of CatS from both the tumour and tumour-associated cells, reflecting the distribution of the protease that has been observed clinically. 15 Figure   S1 ). Western blotting was also used to analyse the levels of CatS, but this proved inconclusive due to high background levels (data not shown).
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Previously, we have shown that in human tumour lines, secreted CatS can promote invasion, which could be blocked with a CatS specific antibodybased inhibitor, Fsn0503. 13 Here, we were able to confirm that Fsn0503 similarly inhibited MC38 cell invasion in a dose dependent manner (p = 0.002 at 500 nM) ( Figure 1C ). Taken together, these data demonstrate expression of CatS by MC38 cells, which promotes their invasive potential in a manner akin to what we have previously observed in human tumour cell lines. 13
Gene silencing of CatS in MC38 cells reduces tumour cell invasive potential
The establishment of CatS-depleted MC38 cell lines was undertaken using retroviral shRNA constructs specific for murine CatS in parallel with a scrambled control. The knockdown of CatS was initially analysed by RT-PCR,
where CatS-specific shRNA constructs 3 (S3) and 4 (S4) yielded the most efficient knockdown in CatS mRNA levels (Figure 2A ). The effect of CatS knockdown clearly reduced the invasive nature of the transduced cells with the most significant reduction observed in the MC38 S4 cells (62%, p = 0.0001) ( Figure 2B , experiments carried out at least 3 times). This inhibition is more pronounced than in Figure 1C which is as expected as the antibodybased inhibitor used in Figure 1C will only target extracellular CatS as S4 cells shown in Figure 2C ). The MC38 S4 cells were also examined for CatS-like activity, revealing a 59% reduction when compared to both the MC38 Sc cells and un-transfected MC38 cells ( Figure 2D) .
A live-cell proteolysis assay was undertaken to compare the MC38 S4 and Sc cells in the presence of DQ-gelatin, which upon degradation emits a bright green fluorescence. The degradation of this substrate in the pericellular environment was noticeably blunted by depletion of CatS ( Figure 2E ), which is in agreement with effects we previously observed in human cell lines with Fsn0503. 13 It is possible that the marked difference we observed was due to alterations in secreted MMP activity, such as MMP2 and MMP9, induced by the deletion of CatS. To address this, supernatants from the cell lines were analysed in a fluorimetric activity assay using a pan-MMP internally quenched substrate, but little difference was observed (Supplementary Figure S2 ).
Finally, prior to in vivo experimentation, alterations in the proliferation rate of the MC38 S4 cells when compared to the MC38 Sc control cells was also examined with no discernable differences observed (Supplementary Figure   S3 ).
Depletion of host and tumour-derived CatS attenuates tumour development
In order to first evaluate the contribution of CatS from host cell-derived CatS in the syngeneic model, parental MC38 cells were injected into both C57Bl/6
WT and CatS -/mice. Daily tumour measurements clearly showed that progression of these tumours was significantly attenuated in the CatS -/mice 14 with a 52% reduction (p = 0.023) in tumour burden observed after 16 days when compared to the tumours from the WT mice ( Figure 3A ). To confirm that these effects were not specific to MC38 cells, a similar study was performed using B16-F10 cells. Again, a significant reduction in tumour growth was apparent in the tumours from the CatS -/mice with a 55% (p = 0.015) reduction in tumour burden observed after 14 days ( Figure 3B ).
With the importance of host cell-derived CatS in tumour progression established, the contribution of the protease from the tumour cells was then evaluated. The CatS-depleted MC38 S4 and scrambled control Sc cells were propagated in both CatS -/and WT mice. In the initial stages of the study, it appeared that the absence of host CatS was the predominant factor in comparison to tumour-derived CatS, given that by day 10, depletion of the tumour-derived protease had no discernable effect ( Figure 3C ). However, after 15 days it was apparent that depletion of CatS from either the tumour cells or the microenvironment similarly attenuated tumour development ( Figure 3C ). Nonetheless, the most pronounced effect was observed when CatS was ablated from both tumour and tumour associated cells (65.7% reduction, p = 0.0016). in Supplementary figure S4) . To examine the neovascularisation in more detail, immunohistochemical staining for the endothelial marker, CD34, was performed. This clearly distinguished the neovasculature in the tumours, as highlighted with arrows in Figure 4A . Quantitative analysis of CD34-positive mean vessel number (MVN) from the tumour sections revealed that when CatS was deleted from both the tumour and tumour-associated cells, a significant reduction in MVN was observed (p = 0.0001) ( Figure 4B ). The mean vessel area was also measured in these sections showing that CatS depletion from either source resulted in a significant reduction in vessel area.
Tumour vascularisation and tumour vessel functionality is reduced in
CatS-depleted tumour microenvironment
However as before, the most pronounced effects were observed when the protease was removed from all cell types (p = 0.0001) ( Figure 4C ).
Further qualitative evidence that the tumour vasculature was affected by CatS depletion was provided through perfusion of FITC-labelled lectin to identify functional vasculature. This indicated that the vessels appeared more poorly defined in the tumours that lacked CatS from both tumour and tumourassociated cells (Supplementary figure S5) . Moreover, the depletion of CatS from either source clearly promoted leakiness of the neovasculature as determined by Evan's blue perfusion, with the most marked effects observed in tumours lacking the protease from both sources (p = 0.0289) ( Figure 4D ).
Given the pronounced effects observed on tumour angiogenesis, tumour lysates from the tumour and host CatS positive (WT with Sc cells) versus the tumour and host CatS negative (-/-with the S4 cells) arms were analysed for several angiogenic factors to determine if they were altered by depletion of
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CatS where it was found that both acidic and basic FGF levels were increased ( Figure 4E ).
CatS depletion results in reduced proliferation and increased apoptosis in tumours
On the basis of the effects observed on tumour neovascularisation, we next examined the tumours for possible alterations in proliferation and apoptosis via Ki67 and TUNEL staining, respectively. The MC38 tumours from all four arms of the investigation stained intensely for Ki67. When CatS was depleted from either the tumour cells or host cells alone, no significant reduction in tumour cell proliferation was apparent ( Figure 5A and 5B). However, when
CatS was depleted from both sources, a significant reduction in proliferation was clearly observed (17% reduction, p = 0.0017) ( Figure 5B ).
Furthermore, we also examined the tumour sections for apoptosis by TUNEL staining and as highlighted by arrows in Figure 5C , it was found that the decrease in proliferation was complimented by an increase in apoptosis, again most significantly when CatS was depleted from both tumour and tumour associated cells (p = 0.0012) ( Figure 5D ).
Tumour, macrophage and endothelial cells contribute CatS to the tumour microenvironment
Finally, we wished to further clarify the different cellular contributors of CatS to the microenvironment in these MC38 tumours. Immunohistochemical detection of CatS from the tumours using the MC38 Sc line in the WT animals 
Discussion
In this current study, we aimed to bridge the gap between clinical observations and prior murine studies, whereby the contribution of CatS from Cysteine cathepsins have previously been implicated in tumourigenesis, facilitating various tumour-associated processes such as invasion, metastasis and angiogenesis. 8, 23 However, amongst these proteases, CatS has unique properties in that it is stable at neutral pH and is a potent elastase and collagenase. 24 Furthermore, it has been suggested to have more physiological importance than other cysteine cathepsins in processing proteins in the extracellular microenvironment. 25 Indeed, given that CatS has been shown to promote the activation of other cysteine cathepsins and normally demonstrates restricted expression largely confined to APCs, 1,25 it may represent a more pertinent therapeutic target than other family members in cancer.
The de-regulated expression of CatS has been identified in a range of human tumour types including lung, brain, colorectal and prostate carcinomas. [11] [12] [13] [14] [15] [16] [17] 26 It is known that CatS can be up-regulated by a number of tumour-associated angiogenic factors such as VEGF and bFGF, 20, 27 but mechanisms underpinning this remain poorly defined and clearly warrant research in the future.
Interestingly, recent analysis of over 3100 tumour specimens across 26 cancers, established that chromosome region 1q21.2 where the CatS gene is located is frequently somatically amplified. This is a consequence of the addiction of tumours to the anti-apoptotic gene Mcl-1 found at this locus, and therefore, it is possible that the up-regulation of CatS may be a collateral effect of tumours adopting this anti-apoptotic phenotype. 28 In this current study, the major effect caused by the stratified deletion of CatS clearly highlighted deficiencies in developing tumour neovasculature. The analyses revealed that loss of CatS reduced the mean vessel number and area and resulted in impaired functionality of the tumour vasculature. These effects are in agreement with previous studies that have highlighted a clear pro-angiogenic role for CatS in tumour development. 10, 13, 18, 19 The impact of impaired tumour vascularization and integrity was complemented with a clear reduction in proliferation and increased apoptosis in these tumours. This is in agreement with the observations of Wang et al. using the RIP1-Tag2 model. 18 Interesting, another study using the same RIP1-Tag2 model observed no alterations in proliferation with CatS deletion, which may be attributed to differences in study design or assays employed. 10 Given that no effect was observed on the proliferation rate of the transfected MC38 cells in vitro, the noted reduction in vivo may be attributed to defective tumour vascularisation. neovascularization caused by the lack of CatS, which has been observed previously with other anti-angiogenic compounds. 29, 30 An additional finding noted in this present model was that vessel leakiness within the tumours was increased in the absence of CatS. This could be a consequence of improper ECM and/or endothelial cell-to-cell junction proteolytic processing, mediated by CatS. This suggests that CatS may have more intricate roles in controlling neoangiogenesis. Indeed, a recent investigation into post-translational modification of endostatin showed that CatS may also have anti-angiogenic roles, 31 highlighting that this protease may indeed mediate both pro-and antiangiogenic effects to promote coordinated neovascularization.
In addition to the production of CatS by the tumour cells, further analysis of microenvironmental contributors confirmed that TAMs produced the protease as previously shown in the RIP1-Tag2, MMTV-Pymt and 4T1 tumour models. 10, 19, 21, 34 Here, we also found that endothelial cells were CatS positive, confirming CatS up-regulation previously detected at the mRNA level in murine tumour-associated endothelium. 32 In conclusion, these studies have clearly shown that CatS can be contributed Error bars, SEM. * p = 0.016, ** p = 0.001. 
